Phenotypes Associated with This Genotype

Genotype
MGI:3840587

• Allelic Composition: Tg(KRT14-Birc5)19Gros/0; Trp53^tm1Brd/Trp53⁺
• Genetic Background: involves: 129S7/SvEvBrd * C3H * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

decreased incidence of tumors by chemical induction ( J:81530 )

• fewer transgenic mice develop skin tumors after topical application of DMBA and PMA than Trp53 heterozygote controls

• median time to tumor formation is 25 weeks versus 16 weeks for the Trp53 heterozygote controls

• a lower percentage of mice (71% versus 89%) have tumors 32-weeks after DMBA application compared with controls

• mean tumor burden is 2.29 tumors per mouse compared to 3.0 tumors in controls

• tumor regression is not observed in transgenic mice whereas 10% of tumors in non-transgenic mice regress

• transgenic mice have an increased incidence of atypical papillomas that progress to squamous cell carcinoma

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:81530 )

• fewer transgenic mice develop skin tumors after topical application of DMBA and PMA than Trp53 heterozygote controls

• median time to tumor formation is 25 weeks versus 16 weeks for the Trp53 heterozygote controls

• a lower percentage of mice (71% versus 89%) have tumors 32-weeks after DMBA application compared with controls

• mean tumor burden is 2.29 tumors per mouse compared to 3.0 tumors in controls

• tumor regression is not observed in transgenic mice whereas 10% of tumors in non-transgenic mice regress

• transgenic mice have an increased incidence of atypical papillomas that progress to squamous cell carcinoma